TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

57 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Kidney disease

    A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

    Testing whether empagliflozin is safe and helps children with chronic kidney disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +29 more US sites · Get directions →

    This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Fatty liver disease (NASH/MASH)

    A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

    Testing how efimosfermin alfa compares with placebo for MASH with scarred liver tissue

    💵 May compensate

    📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

    The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Heart / cardiovascular diseaseKidney disease

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney

    📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →

    The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

    ✓ Study care freePhase 3Ages 50+Learn more →
  • Kidney disease

    CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

    Comparing how two beta-blockers work in hemodialysis patients on heart outcomes

    📍 VA Long Beach Healthcare System, Long Beach, CA · Long Beach, CA · +7 more US sites · Get directions →

    The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Parkinson's disease

    A Study of Buntanetap in Participants With PD

    Testing the long-term safety of buntanetap in people with Parkinson’s

    📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

    This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Parkinson's disease

    A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    Testing a Parkinson’s surgery approach to see if it is safe and works

    📍 Banner Sun Health Research Institute · Sun City, AZ · +32 more US sites · Get directions →

    Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

    ✓ Study care freePhase 3Ages 45–75Learn more →
  • Parkinson's disease

    A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

    Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s

    📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →

    The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

    Testing a drug to treat fat buildup liver disease in people with stage 2 or 3 fibrosis

    📍 Akero Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Kidney disease

    A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

    Testing etelcalcetide in children with kidney disease on dialysis

    📍 Childrens Hospital of Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →

    This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.

    ✓ Study care freePhase 3Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

    Testing whether two doses of pegozafermin are safe and work for liver scarring in adults with MASH

    📍 89bio Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Kidney disease

    Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial

    Testing medicines before surgery to reduce bleeding in kidney patients

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

    Testing long-term safety and effectiveness of zigakibart in adults with IgA kidney disease

    📍 Colorado Kidney Care Nephrology · Denver, CO · +6 more US sites · Get directions →

    The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.

    ✓ Study care freePhase 3Ages 18–100Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Fibrosis Lessens After Metabolic Surgery

    Testing whether metabolic surgery can reduce liver scarring in obesity

    💵 May compensate

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

    Testing whether pegozafermin is safe and works for MASH-related liver cirrhosis

    💵 May compensate

    📍 89bio Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Parkinson's disease

    18F-DOPA II - PET Imaging Optimization

    Testing an imaging scan to study Parkinson’s disease using PET

    📍 WC Mackenzie Health Science Centre / University of Alberta Hospital · Edmonton, Alberta · Get directions →

    A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.

    ✓ Study care freePhase 3Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Kidney disease

    Bone in CKD Alkali Response (BICARb Pilot Trial)

    Testing whether potassium citrate improves bone health in people with chronic kidney disease

    📍 Albert Einstein College of Medicine · The Bronx, NY · +1 more US site · Get directions →

    The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are: * To evaluate effects of potassium citrate treatment on bone quality and strength.

    ✓ Study care freePhase 2Ages 5–100Learn more →
  • Parkinson's disease

    Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

    Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions

    📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →

    Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.

    ✓ Study care freePhase 4Ages 45–75Learn more →
  • Kidney disease

    SAfety of Regional Citrate Anticoagulation (SARCA Study)

    Testing the safety of regional citrate blood-thinner use in adults

    📍 John L. McClellan Memorial Veterans' Hospital · Little Rock, AR · +9 more US sites · Get directions →

    This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

    Testing a treatment for adults with chronic kidney disease to help slow progression

    📍 Apogee Clinical Research · Huntsville, AL · +39 more US sites · Get directions →

    This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Patient-driven Management of BP in CKD

    Testing whether pharmacist-guided blood pressure management helps CKD patients lower blood pressure

    📍 Iowa City VA Health Care System, Iowa City, IA · Iowa City, IA · Get directions →

    The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care. 60 Veterans with chronic kidney disease (CKD) will be included in the study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Parkinson's disease

    BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

    Testing a new long-acting levodopa dose to improve “on” time in Parkinson’s

    📍 Cleveland Clinic · Cleveland, OH · Get directions →

    The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias.

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Kidney disease

    Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

    Testing whether a weekly diabetes medicine is safe for people on dialysis

    📍 Unity Health Toronto · Toronto, Ontario · Get directions →

    This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightKidney disease

    Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

    Studying weight-loss support for people with obesity and kidney disease who want a kidney transplant

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Parkinson's disease

    A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    Testing an IV drug in people with early-stage Parkinson’s disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

    ✓ Study care freePhase 3Ages 50–85Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

    Testing a medicine called efruxifermin in people with compensated liver scarring from NASH/MASH

    💵 May compensate

    📍 Akero Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Kidney disease

    📍 Memorial Healthcare System · Hollywood, FL · +7 more US sites · Get directions →

    Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Kidney disease

    Shingrix in Renal Transplant Recipients

    Testing how well and how safely the shingles vaccine works in people with kidney failure before and

    📍 University of Colorado Anschutz · Aurora, CO · +3 more US sites · Get directions →

    The goal of this clinical trial is to learn how well the shingles vaccine (Shingrix) works and how safe it is in adults with kidney failure who are waiting for a kidney transplant, including those who later receive a transplant. The study also aims to find out whether giving an extra (third) dose of the vaccine after transplant improves protection.

    ✓ Study care freePhase 3Ages 18–70Learn more →
  • Parkinson's disease

    Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

    Comparing treatments to see which works better for hallucinations in Parkinson’s disease

    📍 Southern Arizona VA Health Care System, Tucson, AZ · Tucson, AZ · +23 more US sites · Get directions →

    Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions).

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Fatty liver disease (NASH/MASH)

    LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

    Testing whether survodutide helps adults with MASH and moderate to advanced liver scarring

    💵 May compensate

    📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Testing whether survodutide helps adults with NASH/MASH cirrhosis

    💵 May compensate

    📍 The Institute for Liver Health II DBA Arizona Clinical Trials · Peoria, AZ · +39 more US sites · Get directions →

    This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

    Testing an iron-based phosphate binder to lower blood phosphate in dialysis patients

    📍 Renal Consultants Medical Group · Granada Hills, CA · +18 more US sites · Get directions →

    The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels?

    ✓ Study care freePhase 3Ages 12+Learn more →
  • Parkinson's disease

    A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's

    Testing a wearable sensor to track swallowing and drooling problems in people with Parkinson’s

    📍 Northwestern University · Evanston, IL · Get directions →

    The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.

    ✓ Study care freePhase 3Ages 22+Learn more →
  • Fatty liver disease (NASH/MASH)

    A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

    Testing the safety of an injected medicine in people with MASH and F2 or F3 scarring

    💵 May compensate

    📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

    This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • High blood pressureKidney disease

    📍 Research Site · Fairhope, AL · +39 more US sites · Get directions →

    International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

    Studying how nerve cell loss affects thinking ups and downs in Lewy body dementia

    📍 Virginia Commonwealth University · Richmond, VA · Get directions →

    The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan

    ✓ Study care freePhase 4Ages 50–89Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

    Testing whether a protein supplement reduces liver fat in teens with obesity

    📍 Univeristy of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the participants who get the protein supplement have less fat in the liver compared to participants who were in the placebo group. After the 2 month intervention, all participants can continue the study and will all receive the protein supplement for an additional 10-months.

    ✓ Study care freePhase 3Ages 13–18Learn more →
  • Kidney disease

    Empagliflozin Treatment in Kidney Transplant Recipients

    Testing empagliflozin in people with kidney transplants and chronic kidney disease

    📍 Edward Hines Jr. VA Hospital, Hines, IL · Hines, IL · +4 more US sites · Get directions →

    Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging.

    ✓ Study care freePhase 4Ages 19+Learn more →
  • Parkinson's disease

    Personalized Real-Time DBS and PD Mechanisms

    Studying how closed-loop deep brain stimulation and levodopa affect Parkinson’s motor symptoms

    📍 Cleveland Clinic · Cleveland, OH · Get directions →

    A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Kidney disease

    Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

    Testing Envarsus XR versus twice-daily tacrolimus in kidney transplant rejection and blood immune

    📍 Deepa Valvi · Lexington, KY · Get directions →

    This will be a single center, prospective, open-label, randomized, controlled trial comparing Envarsus XR® to twice-daily tacrolimus. The targeted population will be patients with end stage renal disease listed for primary solitary kidney transplant.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Kidney disease

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

    Testing whether pioglitazone can reduce overactive nerve activity in people with chronic kidney

    📍 University of Texas at Arlington · Arlington, TX · +1 more US site · Get directions →

    Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population.

    ✓ Study care freePhase 4Ages 35–70Learn more →
  • Kidney disease

    Oral Iron in Children With Chronic Kidney Disease

    Testing oral iron in children with chronic kidney disease and mild anemia

    📍 Weill Cornell Medicine / New York Presbyterian Hospital · New York, NY · +1 more US site · Get directions →

    This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs.

    ✓ Study care freePhase 4Ages 1–21Learn more →
  • Fatty liver disease (NASH/MASH)

    Estrogen Administration for the Treatment of NASH in Postmenopausal Women

    Testing estrogen to treat nonalcoholic fatty liver disease in women after menopause

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited.

    ✓ Study care freePhase 3Ages 45–70WomenLearn more →
  • Type 2 diabetesKidney disease

    Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

    Testing the safety and effectiveness of injections for people with type 2 diabetes and chronic

    📍 Nephrology Consultants · Huntsville, AL · +39 more US sites · Get directions →

    The purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.

    ✓ Study care freePhase 3Ages 30–80Learn more →
  • Kidney disease

    📍 Phoenix Children's Hospital | Main - Transplant Department · Phoenix, AZ · +18 more US sites · Get directions →

    Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine.

    ✓ Study care freePhase 3Ages 1–17Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    Quantifying Hepatic Mitochondrial Fluxes in Humans

    Measuring liver energy activity in people with type 2 diabetes before and after 16 weeks of insulin

    📍 Texas Diabetes Institute - University Health System · San Antonio, TX · +1 more US site · Get directions →

    In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Parkinson's disease

    Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

    Measuring serotonin 2A brain receptor activity in people with Parkinson’s

    📍 Vanderbilt University Medical Center · Nashville, TN · Get directions →

    It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.

    ✓ Study care freePhase 4Ages 50–85Learn more →
  • Kidney disease

    CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

    Testing whether CoQ10 plus exercise helps people with advanced kidney disease improve muscle and

    📍 University of California Davis Health · Sacramento, CA · +1 more US site · Get directions →

    Frailty and sarcopenia are modifiable risk factors for morbidity and mortality in patients with ESRD. Exercise is the recommended intervention to prevent frailty and sarcopenia, however, many clinical trials have shown limited clinical improvement in muscle mass and physical function.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Kidney disease

    📍 Phoenix Children's Hospital | Main - Transplant Department · Phoenix, AZ · +17 more US sites · Get directions →

    Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine.

    ✓ Study care freePhase 3Ages 1–18Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Comparing Antipsychotic Medications in LBD Over Time

    Comparing medicines to see which works better for hallucinations or delusions in Lewy body disease

    📍 University Health System · San Antonio, TX · +1 more US site · Get directions →

    The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

    ✓ Study care freePhase 4Learn more →
  • Kidney disease

    meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

    Testing how an SGLT2 medicine affects safety and kidney processes in people on peritoneal dialysis

    📍 Toronto General Hospital · Toronto, Ontario · Get directions →

    The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Safety of Short-course of NSAIDs in Pediatric Patients With CKD

    Testing whether short courses of anti-inflammatory pain medicines after surgery raise kidney injury

    📍 Children's Hospital Colorado · Aurora, CO · Get directions →

    The purpose of this study is to determine if non-steroidal anti-inflammatory (NSAID) use in the postoperative setting increases the risk of acute kidney injury (AKI) in pediatric patients with mild-to-moderate chronic kidney disease (CKD). The investigators hypothesize that there is no increased risk.

    ✓ Study care freePhase 4Ages 2–25Learn more →
  • Parkinson's disease

    A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    Testing BHV-8000 for safety and effectiveness in adults with early Parkinson's disease

    📍 Site-049 · Birmingham, AL · +14 more US sites · Get directions →

    A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.

    ✓ Study care freePhase 2Ages 40–85Learn more →